Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2891

1.

Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.

Birkhead GS, Klein SJ, Candelas AR, O'Connell DA, Rothman JR, Feldman IS, Tsui DS, Cotroneo RA, Flanigan CA.

Int J Drug Policy. 2007 Oct;18(5):417-25. Epub 2007 Feb 20. Review.

PMID:
17854731
2.

HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.

Lazarus JV, Shete PB, Eramova I, Merkinaite S, Matic S.

Int J Drug Policy. 2007 Oct;18(5):426-32. Epub 2007 Feb 15.

PMID:
17854732
3.

Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.

Emmanuelli J, Desenclos JC.

Addiction. 2005 Nov;100(11):1690-700. Erratum in: Addiction. 2006 Apr;101(4):616.

PMID:
16277629
4.

Select barriers to harm-reduction services for IDUs in eastern Europe.

Curth NK, Hansson LN, Storm F, Lazarus JV.

Cent Eur J Public Health. 2009 Dec;17(4):191-7.

5.

The effectiveness and safety of syringe vending machines as a component of needle syringe programmes in community settings.

Islam M, Wodak A, Conigrave KM.

Int J Drug Policy. 2008 Dec;19(6):436-41. Epub 2007 Sep 4. Review.

PMID:
17766100
6.

The role of policy in community pharmacies' response to injection-drug use: results of a nationwide Canadian survey.

Myers T, Cockerill R, Millson M, Rankin J, Worthington C.

AIDS Public Policy J. 1996 Summer;11(2):78-88.

PMID:
10915241
7.

Coverage to curb the emerging HIV epidemic among injecting drug users in Pakistan: delivering prevention services where most needed.

Emmanuel F, Fatima M.

Int J Drug Policy. 2008 Apr;19 Suppl 1:S59-64. doi: 10.1016/j.drugpo.2007.12.012. Epub 2008 Feb 20.

PMID:
18281206
8.

Co-infection by human immuno deficiency virus, hepatitis B and hepatitis C virus in injecting drug users.

Devi KhS, Brajachand N, Singh HL, Singh YM.

J Commun Dis. 2005 Mar;37(1):73-7.

PMID:
16637404
9.

Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States.

Holtgrave DR, Pinkerton SD, Jones TS, Lurie P, Vlahov D.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18 Suppl 1:S133-8.

PMID:
9663636
10.

Optimal provision of needle and syringe programmes for injecting drug users: A systematic review.

Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA.

Int J Drug Policy. 2010 Sep;21(5):335-42. doi: 10.1016/j.drugpo.2010.02.001. Epub 2010 Feb 26. Review.

PMID:
20189375
11.
12.

Syringe exchange programs --- United States, 2008.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2010 Nov 19;59(45):1488-91.

13.

Integrating HCV services for drug users: a model to improve engagement and outcomes.

Sylvestre DL, Zweben JE.

Int J Drug Policy. 2007 Oct;18(5):406-10. Epub 2007 Apr 30.

PMID:
17854729
14.
15.

Harm reduction theories and strategies for control of human immunodeficiency virus: a review of the literature.

Hilton BA, Thompson R, Moore-Dempsey L, Janzen RG.

J Adv Nurs. 2001 Feb;33(3):357-70. Review.

PMID:
11251723
16.

Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001.

Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR.

AIDS. 2005 Oct;19 Suppl 3:S20-5.

PMID:
16251819
17.

Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.

Braitstein P, Li K, Kerr T, Montaner JS, Hogg RS, Wood E.

AIDS Care. 2006 Oct;18(7):690-3.

PMID:
16971276
18.

HIV and hepatitis C virus risk in new and longer-term injecting drug users in Oslo, Norway.

Miller M, Mella I, Moi H, Eskild A.

J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):373-9.

PMID:
12843749
19.

Estimating the cost-effectiveness of needle-syringe programs in Australia.

Kwon JA, Anderson J, Kerr CC, Thein HH, Zhang L, Iversen J, Dore GJ, Kaldor JM, Law MG, Maher L, Wilson DP.

AIDS. 2012 Nov 13;26(17):2201-10. doi: 10.1097/QAD.0b013e3283578b5d.

PMID:
22914579
20.

Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.

Rhodes T, Platt L, Judd A, Mikhailova LA, Sarang A, Wallis N, Alpatova T, Hickman M, Parry JV.

Int J STD AIDS. 2005 Nov;16(11):749-54.

PMID:
16303071

Supplemental Content

Support Center